Login to Your Account

Clinic Roundup

Thursday, September 12, 2013
• Ovascience Inc., of Cambridge, Mass., suspended enrollment of a trial with Augment, its candidate designed to improve egg quality and increase the success of in vitro fertilization, because the FDA questioned the status of the product as a human cellular tissue-based product and wants the firm to file an investigational new drug application.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription